{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:11:47Z","timestamp":1792005107196,"version":"4.4.0"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,3,17]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICI) have improved outcomes for patients with many malignancies. However, these treatments are associated with immune-related adverse events, including pulmonary toxicity (pneumonitis). Pneumonitis is associated with significant short-term morbidity and mortality, but long-term outcomes are not well described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used the Vanderbilt Synthetic Derivative, a deidentified electronic health record database of &gt;2.5\u2009million patients seen at Vanderbilt, to identify patient charts that included treatment with pembrolizumab, nivolumab, ipilimumab, ipilimumab and nivolumab, atezolizumab or durvalumab by keyword search and ICD-10 codes for acute respiratory failure and\/or bronchoalveolar lavage. We manually reviewed these charts and identified 78 subjects who met criteria for probable pneumonitis which included patients presenting with symptoms (dyspnoea, hypoxia, cough) and\/or CT imaging consistent with this diagnosis. We collected data on demographics, ICI regimen, hospital admissions and long-term survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 78 patients (48 males; median age 64 (range 28\u201381)), 52 patients required at least 1 hospital admission related to pneumonitis. A total of 25 patients experienced poor short-term outcomes (including 6 referred to hospice, 11 discharged to rehabilitation and 9 deaths). There was no association with these outcomes by patient age (p=0.96), sex (p=0.60), smoking status (p=0.63) or cancer type (p=0.13). Median duration of follow-up was 8.3 months (range 0.2\u2013110.6 months), and 29 patients (37%) were alive at last follow-up. Patients admitted to the hospital were more likely to die (p=0.002) and less likely to receive additional treatment (p&lt;0.0001) or survive for \u226512 months with no evidence of disease (p=0.02). There were no differences in long-term outcomes for patients with underlying pulmonary comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>ICI-pneumonitis has a high likelihood of causing hospitalisation and poor outcomes, including death. While there appears to be no difference in outcomes for patients with underling pulmonary comorbidities, those requiring admission have worse outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001342","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T12:04:33Z","timestamp":1685448273000},"page":"e001342","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-3432","authenticated-orcid":false,"given":"Andrea","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Bastarache","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"2025083112271453000_10.1.e001342.1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"2025083112271453000_10.1.e001342.2","doi-asserted-by":"publisher","DOI":"10.1159\/000509941"},{"key":"2025083112271453000_10.1.e001342.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.08.014"},{"key":"2025083112271453000_10.1.e001342.4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025083112271453000_10.1.e001342.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.09.015"},{"key":"2025083112271453000_10.1.e001342.6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1579"},{"key":"2025083112271453000_10.1.e001342.7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12759"},{"key":"2025083112271453000_10.1.e001342.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.001"},{"key":"2025083112271453000_10.1.e001342.9","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv532.43","article-title":"459P risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001","volume":"26","author":"Ahn","year":"2015","journal-title":"Annals of Oncology"},{"key":"2025083112271453000_10.1.e001342.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1202ST"},{"key":"2025083112271453000_10.1.e001342.11","doi-asserted-by":"publisher","DOI":"10.1159\/000503566"},{"key":"2025083112271453000_10.1.e001342.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30380-7"},{"key":"2025083112271453000_10.1.e001342.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.11.027"},{"key":"2025083112271453000_10.1.e001342.14","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13240"},{"key":"2025083112271453000_10.1.e001342.15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0102"},{"key":"2025083112271453000_10.1.e001342.16","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005"},{"key":"2025083112271453000_10.1.e001342.17","unstructured":"Department of human resource U . Common terminology criteria for adverse events (CTCAE).v.5.0. Cancer Ther Eval Progr 2017."},{"key":"2025083112271453000_10.1.e001342.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025083112271453000_10.1.e001342.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025083112271453000_10.1.e001342.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02536-5"},{"key":"2025083112271453000_10.1.e001342.21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0674"},{"key":"2025083112271453000_10.1.e001342.22","doi-asserted-by":"publisher","DOI":"10.4103\/JIPO.JIPO_12_18"},{"key":"2025083112271453000_10.1.e001342.23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"2025083112271453000_10.1.e001342.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.016"},{"key":"2025083112271453000_10.1.e001342.25","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13187"},{"key":"2025083112271453000_10.1.e001342.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.07.006"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:27:22Z","timestamp":1756668442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,6]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/bmjresp-2022-001342"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001342","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}